BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Definiens AG Appoints Professor Dr. Ralf Huss as Chief Medical Officer


2/26/2013 11:53:38 AM

Munich, Germany, February 26, 2013 / B3C newswire / – Definiens, the global leader of image and data analysis solutions for quantitative digital pathology, today announced the appointment of renowned surgical and anatomical pathologist Dr. Ralf Huss as Chief Medical Officer (CMO). Professor Huss brings significant expertise in pathology and will play a key role in expanding Definiens’ leading position in image and data analysis for Digital Pathology in Life Sciences into Tissue Diagnostics and Clinical Digital Pathology.

“We are very pleased that Professor Huss is assuming the role of the Chief Medical Officer for Definiens. Professor Huss’ expertise will be invaluable in further strengthening Definiens’ leading role in quantitative digital pathology for life science research, tissue diagnostics development and clinical routine,” said Thomas Heydler, CEO of Definiens. “We’re thrilled to have a highly regarded industry luminary consult the leadership team who will build upon Definiens’ expertise in pathology following the closure of a recent financing round.”

Professor Huss has more than 20 years of training and experience in histopathology and cancer research, and served previously as Global Head of Histopathology and Tissue Biomarker at Roche Diagnostics, where he was involved in identifying new tissue biomarkers to stratify cancer patients as part of a global Personalized Healthcare strategy. Professor Huss also co-founded the biotech company APCETH for which he remains a member of the management team. In addition Professor Huss holds national and international academic appointments at the Ludwig-Maximilians-University Munich (Germany) and the Wake Forest Institute for Regenerative Medicine (USA).

“I am very pleased to advise Definiens and support the outstanding work the company is doing in the field of clinical digital pathology,” said Professor Huss. “Novel tissue diagnostics will be essential in bringing the vision of personalized medicine to fruition. Definiens leadership position in Image and Data Analysis in Life Sciences is a perfect starting point to advance the development of tissue and companion diagnostics, and to ultimately offer ground breaking solutions for Clinical Digital Pathology. I am very much looking forward to contributing to the company’s growth and innovation in the role of Chief Medical Officer.”

About Definiens

Definiens is the leading provider of image analysis and data mining solutions for life sciences, tissue diagnostics and clinical digital pathology. Definiens software provides detailed cell-by-cell readouts from target structures on whole tissue slides, and allows the correlation of this information with data derived from other sources. By automating analysis workflows, Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists to generate new knowledge and support better decisions in research, diagnostics and therapy. Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients’ lives.

Definiens is headquartered in Munich, Germany and has offices throughout the United States.

Media Contact

Definiens AG

Dr Florian Leiss

Manager Marketing Communications

+49 (89) 2311-8024

fleiss@definiens.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES